Drug Targets – Multimedia

What if I told you Hybrigenics Services can help you make the right decisions and optimize the success rate of your drug discovery and development programs?
Watch how with our animation video and discover our optimized ULTImate YChemH technology for drug target deconvolution.

Previous studies suggested that Mycobacterium tuberculosis obtains nitrogen from a diverse range of intracellular nutrients including amino acids. Here, we use a novel system’s based three-pronged approach to define pathways for uptake and assimilation of nitrogen.

Just when you thought you’d got to grips with the idea of big data, a whole new set of buzzwords comes along: artificial intelligence, machine learning, deep learning, structured and unstructured data. But for the pharmaceutical industry right now these are more than just buzzwords, they are the promise of a new era of productivity.

G protein-coupled receptors (GPCRs) are the largest human membrane protein family. This infographic summarizes approved and investigational drugs, GPCR targets, and associated indications.

2017 has been an exciting year for the drug discovery field. This list details the top 10 most-read news stories we published from the field this year.

This list highlights four approaches used to assess toxicology within the field of drug discovery.

This article highlights some of the wide range of applications which can be achieved using mass spectrometry.

We will describe a novel approach to target such ion channels with antibody-based drugs and present a case study where functional channel-closing and modulating antibodies have been successfully identified to a ligand-gated ion channel.

This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.

Loss-of-function genetic screens with pooled sgRNA and shRNA libraries aid in discovery / prioritization of drug targets, understanding of disease progression and gene-disease associations, analysis of signal transduction pathways, characterization of the mechanisms for compounds, uncovering of synergistic gene interactions, and identification of markers of drug resistance and sensitivity. This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.